lutazone is indicated as the second or third line of therapy for type 2 diabetes: as monotherapy: in adult patients (especially overweight patients) with contraindications or intolerance to Metformin in the case of inadequate control of blood sugar levels by diet and exercise; double therapy in combination with: Metformin in adult patients (especially overweight patients) with insufficient glycemic control, despite the use of Metformin monotherapy in the maximum tolerated dose; sulfonylurea derivatives in adult patients with intolerance and contraindications to Metformin) with insufficient glycemic control, despite the use of monotherapy with sulfonylurea derivatives in the maximum tolerated dose; as a triple therapy in combination with: Metformin and sulfonylurea derivatives in adult patients (especially overweight) with insufficient glycemic control, despite the use of dual combination therapy.
Gliutazon №28 Storage:
active substance: pioglitazone
1 tablet contains pioglitazone hydrochloride equivalent to pioglitazone 15 mg or 30 mg or 45 mg
Excipients: lactose monohydrate calcium hydroxypropylcellulose carboxymethylcellulose magnesium stearate.
Gliutazon №28 Dosage form.
Basic physical and chemical properties:
15 mg tablets:
30 mg tablets: White round biconvex tablets smooth on both sides
45 mg tablets: White round biconvex tablets smooth on both sides.
Antidiabetic drugs. Hypoglycemic agents other than insulins. Thiazolidinediones.
ATX code A10B G03.
Gliutazon №28 Pharmacological properties.
In patients with impaired lipid metabolism with the use of pioglitazone due to stimulation and PPAR-alpha is activated catabolism of inflammatory mediators decreases the thickness of the inner wall of the arteries by eliminating inflammatory and proliferative processes decreases fibrinogen levels in plasma and decreases levels of triglycerides density) while the level of LDL (low density lipoprotein) and total cholesterol does not change.
Absorption. After oral administration of pioglitazone is rapidly absorbed, maximum plasma concentrations of unchanged pioglitazone are usually reached within 2 hours after ingestion. A proportional increase in plasma concentration was observed for doses from 2 to 60 mg. Stable state is achieved after taking the drug for 4 – 7 days. Repeated use does not lead to accumulation of the drug or its metabolites. Eating does not affect absorption. The absolute bioavailability of pioglitazone exceeds 80%.
In vitro studies have not shown any evidence that pioglitazone inhibits any subtype of the cytochrome P450 system. In humans, there is no induction of the main isoenzymes of the cytochrome P450 1A 2C8 9 and 3A4 system.
Hypersensitivity to the active substances or to any of the components of the drug.
Insulin-dependent diabetes mellitus type I.
Heart failure (stages I – IV NYHA).
Bladder cancer is present or in the anamnesis.